Madrigal Pharma (MDGL) Tops Q3 EPS by $1.84, Beats on Revenue

Madrigal Pharma (NASDAQ: MDGL) reported Q3 EPS of ($4.92), $1.84 better than the analyst estimate of ($6.76). Revenue for the quarter came in at $62.2 million versus the consensus estimate of $34.09 million.

For earnings history and earnings-related data on Madrigal Pharma (MDGL) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• Bending Spoons valuation up to $19 Billion in U.S. IPO - Reuters
• Incyte (INCY) PT Raised to $105 at Truist Securities